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Aims The E3-ligase CBL-B (Casitas B-cell lymphoma-B) is an important negative regulator of T cell activation that is also
expressed in macrophages. T cells and macrophages mediate atherosclerosis, but their regulation in this disease




The expression of CBL-B in human atherosclerotic plaques was lower in advanced lesions compared with initial
lesions and correlated inversely with necrotic core area. Twenty weeks old Cblb/Apoe/ mice showed a signifi-
cant increase in plaque area in the aortic arch, where initial plaques were present. In the aortic root, a site contain-
ing advanced plaques, lesion area rose by 40%, accompanied by a dramatic change in plaque phenotype. Plaques
contained fewer macrophages due to increased apoptosis, larger necrotic cores, and more CD8þ T cells.
Cblb/Apoe/ macrophages exhibited enhanced migration and increased cytokine production and lipid uptake.
Casitas B-cell lymphoma-B deficiency increased CD8þ T cell numbers, which were protected against apoptosis and
regulatory T cell-mediated suppression. IFNc and granzyme B production was enhanced in Cblb/Apoe/ CD8þ
T cells, which provoked macrophage killing. Depletion of CD8þ T cells in Cblb/Apoe/ bone marrow chimeras
rescued the phenotype, indicating that CBL-B controls atherosclerosis mainly through its function in CD8þ T cells.
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Conclusion Casitas B-cell lymphoma-B expression in human plaques decreases during the progression of atherosclerosis. As an
important regulator of immune responses in experimental atherosclerosis, CBL-B hampers macrophage recruit-
ment and activation during initial atherosclerosis and limits CD8þ T cell activation and CD8þ T cell-mediated
macrophage death in advanced atherosclerosis, thereby preventing the progression towards high-risk plaques.
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Introduction
Atherosclerosis, a lipid-driven inflammatory disease of the large
arteries, is the underlying cause of the majority of cardiovascular dis-
eases (CVD).1 Although primary and secondary preventive strategies
have significantly lowered the incidence of CVD, atherosclerosis
remains a major cause of morbidity and mortality.2 Additional thera-
peutic strategies, which target the residual cardiovascular risk that
persists after optimal pharmacological treatment, are therefore
required.2 In addition to dyslipidaemia, immune cell activation and
subsequent inflammation drive atherogenesis.1–3 Inhibition of
atherosclerosis-associated inflammation is therefore a strategy with a
great therapeutic potential, as highlighted by the CANTOS
(Canakinumab Antiinflammatory Thrombosis Outcome Study) trial,
in which antibody-mediated inhibition of interleukin (IL)-1b reduced
the incidence of recurrent CVD in patients with a previous myocar-
dial infarction and high residual inflammatory risk.4
T cells constitute a variable but substantial proportion of the im-
mune cell population in the atherosclerotic plaque and are significant
drivers of the inflammatory responses that underlie atherosclerosis.1,3
CD4þ T cells are the predominant T cell subset in atherosclerotic
lesions of Apolipoprotein E-deficient (Apoe/) mice. However, sub-
sets of CD4þ T cells contribute differently to atherosclerosis.1 While
T helper (Th)1 cells are considered pro-atherosclerotic, Th2 cells are
still controversially discussed.1 Regulatory T cells (Tregs) are consid-
ered protective in atherosclerosis through the release of transforming
growth factor (TGF)b and IL10.1 The function of CD8þ cytotoxic T
cells in atherosclerosis is incompletely understood; however, they ap-
pear proatherogenic and are abundantly present in advanced human
atherosclerotic lesions.3 Transfer of CD8þ T cells accelerates athero-
sclerosis and leads to a vulnerable plaque phenotype in Apoe/ mice,
whereas antibody-mediated depletion of CD8þ T cells impedes the
formation of atherosclerotic lesions.3,5,6 Despite the well-described
functions of T cell subsets in atherosclerosis, the regulatory mecha-
nisms by which they undergo activation and polarization during
atherogenesis are less extensively studied.
The Casitas B-cell lymphoma (CBL) E3 ubiquitin ligases—
comprising CBL-B, C-CBL, and CBL-C—form one of the protein
families that modulate T cell activation and polarization.7 Casitas B-cell
lymphoma-B promotes T cell tolerance through ubiquitination and
degradation of downstream effectors, such as phosphoinositide
phospholipase Cc and phosphoinositide 3-kinase, and thus is a nega-
tive regulator of T cell activation.7,8 Casitas B-cell lymphoma-B-defi-
cient T cells have a hyper responsive phenotype that is accompanied
by CD28-independent activation, due to their lower threshold for
T cell receptor-mediated responses.9 Further, these T cells
mount delayed responses to anergic signals, contributing to a
state of hyper responsiveness.10
Notably, macrophages, an important cell type that abounds in ath-
erosclerotic plaques, also expresses CBL-B, the function of which in
this cell type remains incompletely described.7 Casitas B-cell lymph-
oma-B deficiency is linked to enhanced toll-like receptor (TLR)4 sig-
nalling and increased macrophage activation and migration in diet-
induced obesity11 and lung inflammation models,12 processes that
are also relevant for the atherosclerosis.
Considering the significant regulatory activity of CBL-B in T cell
and macrophage biology, we evaluated the expression pattern of
CBL-B in human atherosclerotic lesions and investigated the function
of CBL-B in experimental atherosclerosis.
Methods
Human studies
Coronary artery specimens were obtained from autopsy from the
Department of Pathology of the Amsterdam UMC and immediately fixed
in 10% formalin and processed for paraffin embedding. All use of tissue
was in agreement with the ‘Code for Proper Secondary Use of Human
Tissue in the Netherlands’. CBL-B expression was analysed by immuno-
histochemistry, as described in the Supplementary material online. Gene
expression of CBL-B in human atherosclerosis was examined by
microarray-based transcriptional profiling of carotid endarterectomy
specimens (BiKE dataset13,14).
Animal studies
Male Cblb/Apoe/ and Apoe/mice were bred and housed at the ani-
mal facility of the University of Amsterdam and kept on a normal chow
diet. All mice were treated according to the study protocol (permit nos.
102601 and 102869) that were approved by the Committee for Animal
Welfare of the University of Amsterdam, the Netherlands. Detailed
methods are provided in the Supplementary material online.
Translational perspective
In this study, we demonstrate that the E3-ligase Casitas B-cell lymphoma-B (CBL-B) is expressed in human atherosclerotic plaques,
and that its expression decreases with plaque progression. Using an atherosclerotic mouse model, we found that CBL-B exerts pro-
found anti-atherogenic effects by regulating CD8þ T cell and macrophage activation. Activation of CBL-B, therefore, represents a
promising anti-inflammatory therapeutic strategy in atherosclerosis.

































































































Casitas B-cell lymphoma-B co-localizes
with macrophages and T cells in human
atherosclerotic plaques
Human coronary atherosclerotic plaques, histologically classified as
intimal xanthomas or pathological intimal thickenings (initial/inter-
mediate atherosclerosis) expressed higher levels of CBL-Bþ cells
when compared with fibrous cap atheromata (advanced atheroscler-
osis) (Figure 1A–C). A negative correlation between plaque area and
CBL-B expression (Figure 1D), and necrotic core area and CBL-B was
observed (Figure 1E), indicating that CBL-B expression in the plaque
decreased during the progression of atherosclerosis. The majority of
CBL-Bþ cells were CD68þ macrophages (Figure 1F) and CD3þ T
cells (Figure 1G), whereas only few intraplaque vascular smooth
muscle cells (VSMCs) and endothelial cells expressed CBL-B (data
not shown).
To further evaluate the expression of CBL-B in human athero-
sclerosis, gene expression of CBL-B in carotid endarterectomy speci-
mens was examined by microarray-based transcriptional profiling
(BiKE dataset13,14) Carotid atherosclerotic lesions had a tendency to
express less CBL-B mRNA when compared with non-atherosclerotic
arteries (P= 0.056) (Figure 1H). Casitas B-cell lymphoma-B was not dif-
ferentially expressed between atherosclerotic plaques from symp-
tomatic and asymptomatic patients (data not shown), indicating that





Casitas B-cell lymphoma-B is expressed in CD68þ macrophages and
CD3þ T cells in murine atherosclerotic plaques (Supplementary ma-
terial online, Figure S1). To study the function of CBL-B in athero-
sclerosis, Cblb/Apoe/ and Apoe/ mice were generated and fed
a normal chow diet for 20 weeks. The extent and phenotype of ath-
erosclerosis was determined in the aortic arch and the aortic root
(Figure 2A). Body weight or basic haematologic parameters did not
differ between genotypes (Supplementary material online, Table S1).
Histological analysis of over 20 organs revealed no abnormalities,
particularly no signs of autoimmunity, in Cblb/Apoe/ or Apoe/
mice.
Deficiency of CBL-B increased atherosclerotic plaque area in the
aortic arch and its main branch points by 1.8-fold (Figure 2B and C).
Most plaques in the aortic arch were early, macrophage rich lesions
(Figure 2C). Immunohistochemistry demonstrated that the plaques of
Cblb/Apoe/ mice contained significantly more CD45þ cells
(Figure 2D), reflecting a more inflammatory plaque phenotype.
Plaques in the aortic roots of Cblb/Apoe/ and Apoe/ mice
were not only larger (Figure 2E), but also displayed hallmarks of
advanced stages of atherosclerosis, especially necrotic core forma-
tion (Figure 2F). Deficiency of CBL-B resulted in a 1.4-fold increase in
atherosclerotic plaque area. Plaques in the aortic root of
Cblb/Apoe/ mice contained fewer CD68þ macrophages when
compared with Apoe/ mice (Figure 2G and H), which resulted from
increased macrophage apoptosis (Figure 2I) and a subsequent
increase in necrotic core area (Figure 2J and K). In line with the more
advanced plaque phenotype, collagen content increased in plaques of
Cblb/Apoe/ mice (30.4± 2.6% Apoe/ vs. 45.0 ± 3.8%
Cblb/Apoe/), whereas plaque VSMC content (2.1 ± 0.3 Apoe/
vs. 2.0 ± 0.1% Cblb/Apoe/) did not differ. Thus, deficiency of
CBL-B increased plaque inflammation and macrophage death, there-
by accelerating the progression of atherosclerosis.
Casitas B-cell lymphoma-B deficiency
induces an atherogenic phenotype in
macrophages
Considering the profound increase in early, macrophage-rich lesions
observed in the aortic arch and incremented necrotic core formation
in the more advanced stages of atherosclerosis in Cblb/Apoe/
mice, we analysed the effects of CBL-B on monocytes and
macrophages.
Deficiency of CBL-B increased the expression of the chemokine
receptors CCR1, CCR2, and CCR5, all of which mediate leucocyte re-
cruitment into the arterial wall, in primary monocytes and bone
marrow-derived macrophages (BMDMs) (Figure 3A and B).
Transcript levels of CCR7, a chemokine receptor that governs macro-
phage egress in atherosclerosis,15 also increased (Figure 3A and B).
Consistent with these findings, Cblb/Apoe/ monocytes and
BMDMs exhibited an increased migratory capacity towards CCL2
(Figure 3C and D).
Lipopolysaccharide stimulated Cblb/Apoe/ BMDMs produced
significantly more reactive oxygen species (ROS) (Figure 3E and F),
TNF (Figure 3G and H), and IL6 (Figure 3I), whereas IL10 expression
was reduced (Figure 3J). Moreover, CBL-B-deficient BMDMs
expressed significantly more MHC-II, pointing towards increased
antigen presenting capacity of these cells (Figure 3K). Expression of
the M1 macrophage marker iNOS was increased in aortic arch lysates
of Cblb/Apoe/ mice, the M2 markers arginase 1 and CD206 were
not affected (Supplementary material online, Figure S2A).
Upon phagocytosis and cytoplasmic storage of lipoproteins, mac-
rophages evolve into foam cells, the predominant constituent of ath-
erosclerotic plaques. Notably, CBL-B transcript levels decreased
during foam cell formation (Supplementary material online, Figure
S2B). Casitas B-cell lymphoma-B-deficient BMDMs expressed higher
protein levels of the scavenger receptor CD36 (Figure 3L) and
ingested significantly more oxLDL (Figure 3M), whereas the choles-
terol efflux genes ABCA1 and ABCG1 were not affected
(Supplementary material online, Figure S2C). Thus, deficiency of CBL-
B enhanced the migratory potential of macrophages, promoted the
expression of inflammatory mediators and increased lipid uptake,
resulting in an atherogenic macrophage phenotype.
Casitas B-cell lymphoma-B deficiency
increases the abundance of CD8þ T cells
by reducing apoptosis and regulatory
T-cells-mediated suppression
As CBL E3 ubiquitin ligases modulate T cell activation and polariza-
tion, we investigated T cell appearance in plaques of Cblb/Apoe/
and Apoe/ mice. Immunohistochemistry demonstrated a trend to-
wards increased CD3þ T cell abundance in the advanced plaques of


























the aortic roots of Cblb/Apoe/ mice (8.0± 3.2% Apoe/ vs.
12.0± 3.2% Cblb/Apoe/; P¼ 0.08), specifically due to a significant
increase in cytotoxic CD8þ T cells (2.05 ± 1.41% Apoe/ vs.
5.00± 2.05% Cblb/Apoe/; P¼ 0.003) (Figure 4A and B). These
findings were supported by flow cytometry, verifying skewing to-
wards more CD8þ T cells in the aortic arch, blood and spleen
(Figure 4C). In the absence of CBL-B, CD8þ T cells shifted from naı¨ve
(CD44-CD62Lþ) to central memory T cells (CD44þCD62Lþ) with
no differences in the effector memory T cell compartment
(CD62L-CD44þ) (Figure 4D), suggesting enhancement of their activa-
tion status.
Next, we studied the potential mechanism underlying the
increased abundance of CD8þ T cells and found that CBL-B defi-
ciency enhanced the production of IL2 (Figure 4E and F), a potent
growth factor for T cells. Casitas B-cell lymphoma-B-deficient CD8þ T
cells were also protected against TNF-induced apoptosis as demon-
strated by lower expression of annexin V (Figure 4G). Corroborating
this finding, more Cblb/Apoe/ CD8þ T cells contained the anti-
apoptotic B cell lymphoma 2 (Bcl2) protein (Figure 4H). Moreover,
Cblb/Apoe/ CD8þ T cells were more resistant to Treg-mediated
suppression than Apoe/ CD8þ T cells and underwent more vigor-
ous proliferation at various CD8þ T cell:Treg ratios (Figure 4I).
Figure 1 Casitas B-cell lymphoma-B is expressed in human atherosclerotic lesions and co-localizes with macrophages and T cells. (A)
Immunohistochemical analysis of CBL-B expression in initial/intermediate and advanced human coronary atherosclerotic lesions. The percentage of
CBL-Bþ cells in the lesion decreased in the advanced atherosclerotic plaques (n= 5 per plaque phenotype). Representative pictures of (B) CBL-B ex-
pression in initial/intermediate and (C) advanced lesions are shown. Arrows indicate CBL-Bþ cells. A negative correlation between (D) CBL-B expres-
sion and plaque area and (E) CBL-B and necrotic core area was observed. CBL-B expression co-localized with CD68þ cells (F) and CD3þ cells (G),
arrows indicate CBL-BþCD68þ or CBL-BþCD3þ cells, respectively. Scale bar 25lm for all pictures. (H) BiKE database: CBL-B mRNA expression in
carotid endarterectomy specimens (n= 127) when compared with non-atherosclerotic arteries (n= 10). Data are presented as mean ± standard
deviation.
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Figure 2 Casitas B-cell lymphoma-B deficiency aggravates atherosclerosis in Apoe/ mice. (A) Atherosclerosis was analysed in the aortic arch,
where initial plaques were present, and the aortic root, which contained advanced atherosclerotic plaques. (B) Atherosclerotic plaque area in the
aortic arch of 20-week-old Apoe/ (n= 6) and Cblb/Apoe/ (n= 6) mice. (C) Representative longitudinal sections of aortic arches in Apoe/ and
Cblb/Apoe/ mice (the brachiocephalic trunk is shown; haematoxylin and eosin staining). Scale bar: 50lm. (D) Immunohistochemical quantifica-
tion of the relative number of CD45þ cells per plaque (n= 6 per genotype). (E) Aortic roots of 20-week-old Apoe/ (n= 15) and Cblb/Apoe/
(n= 11) mice were used to analyse the amount of atherosclerosis. (F) Representative pictures of haematoxylin and eosin-stained aortic root cross-
sections containing advanced atherosclerotic plaques in Apoe/ and Cblb/Apoe/ mice. Scale bar: 500lm. (G, H) Plaque macrophage content
and representative images of CD68 staining. Scale bar: 200lm. (I) Percentage of apoptotic (TUNELþCD68þ) macrophages in the plaques. (J, K)
Quantification of necrotic core area in plaques of aortic roots. Representative pictures are shown. The black line indicates the necrotic core. Scale
bar: 100lm. Data are presented as mean ± standard deviation.
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Figure 3 Casitas B-cell lymphoma-B deficiency induces an atherogenic phenotype in macrophages. Quantification of mRNA expression of chemo-
kine receptors CCR1, 2, 5, and 7 in monocytes (A) and bone marrow-derived macrophages (B) of Apoe/ (n= 4) and Cblb/Apoe/ (n= 4) mice.
(C) CCL2-induced monocyte migration was increased in Cblb/Apoe/ mice (n= 16 per genotype). (D) Migration of bone marrow-derived macro-
phages from Apoe/ and Cblb/Apoe/ mice towards 10 ng/mL MCP-1 by transwell assay (n= 3 experiments). (E, F) Flow cytometric analysis of
reactive oxygen species production by Apoe/ (n= 8) and Cblb/Apoe/ (n= 6) bone marrow-derived macrophages after 48 h LPS stimulation.
Representative dot plots; numbers indicate percentage of bone marrow-derived macrophages positive for carboxy-H2DCFCA. Representative dot
plot and graph of TNF (G, H) and interleukin-6 (I) production after 24 h exposure to oxLDL (n= 3 experiments). (J) mRNA expression of interleu-
kin-10 in bone marrow-derived macrophages from Apoe/ and Cblb/Apoe/ mice after 24 h exposure to oxLDL (n= 3 experiments). Flow cyto-
metric analysis of MHC-I and MHC-II expression (K) and CD36 expression (L) of bone marrow-derived macrophages (n= 3 experiments). (M) Flow
cytometric analysis of lipid uptake in bone marrow-derived macrophages (n= 6). Data are presented as mean ± standard deviation.
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Figure 4 Casitas B-cell lymphoma-B deficiency increases CD8þ T cell abundance in Cblb/Apoe/ mice by reducing apoptosis and regulatory
T cell-mediated suppression. (A) Percentages of CD8þ T cells in advanced atherosclerotic plaques of aortic roots of 20-week-old Apoe/ (n= 10)
and Cblb/Apoe/mice (n= 7). (B) Representative pictures of anti-CD8 (Alexa Fluor 594, red) staining (DAPI staining: blue). White arrows indicate
CD8þ T cells. Scale bar: 100lm. (C) Flow cytometric analysis of CD4þ and CD8þ T cells in aortic arch, blood, and spleen of Apoe/ and
Cblb/Apoe/ mice (n= 7) (D) Quantification of naı¨ve (CD44-CD62Lþ), central memory (CD44þCD62Lþ), and effector memory
(CD44þCD62L-) CD8þ T cells in spleens of Apoe/ and Cblb/Apoe/ mice. (E, F) interleukin-2 production by CD8þ T cells isolated from
in vitro-restimulated splenocytes (n= 3), Representative dot plots are shown. (G) Fraction of apoptotic (Annexin Vþ) cells of CD3/CD28-activated
isolated splenic CD8þ T cells from Apoe/ (n= 3) or Cblb/Apoe/ (n= 5) mice that were incubated with TNF for 96 h. (H) Flow cytometric ana-
lysis of BCL2 expression in CD8þ T cells (n= 7). (I) Regulatory T cell suppression assay using splenic CD8þ T cells and CD4þCD25þ regulatory T
cells from Apoe/ and Cblb/Apoe/ mice, co-cultured at various ratios (n= 3 experiments). (J) TGFbRII mRNA expression in CD8þ T-cells
isolated from Apoe/ and Cblb/Apoe/ mice (n= 3). Data are presented as mean ± standard deviation.












































..Additionally, TGFb receptor II (TgfbR2) gene expression was
decreased in Cblb/Apoe/ CD8þ T cells, rendering them less sen-
sitive to TGFb-induced Treg-mediated suppression16 (Figure 4J).
Casitas B-cell lymphoma-B deficiency
increases the cytotoxicity of CD8þ T cells
and provokes macrophage death
To further characterize, the effects of CBL-B deficiency on cytotoxic
T cell function, splenic CD8þ T cells were isolated and the produc-
tion of effector proteins was analysed. Cblb/Apoe/ CD8þ T cells
showed a significant increase in IFNc protein levels compared with
Apoe/ CD8þ T cells (Figure 5A and B). Moreover, CBL-B-deficient
cytotoxic T cells expressed higher levels of granzyme B (Figure 5C
and D), a protein described to promote atherosclerosis by inducing
apoptosis in plaque-associated cells.5 Perforin (Apoe/ 1.0± 0.1 vs.
Cbl-b/Apoe/ 1.2± 0.3) and granzyme A (Apoe/ 0.9± 0.1 vs.
Cblb/Apoe/ 1.2 ± 0.3) levels remained unchanged.
To investigate whether the increase in effector protein production
in CBL-B-deficient CD8þ T cells affected the cytotoxicity of these
cells, a macrophage killing assay was performed. Ovalbumin peptide
(OVA257–264) primed CD8þ T cells were co-cultured with
OVA257–264-pulsed CFSEhigh-labelled BMDMs and unpulsed CFSElow-
labelled BMDMs. In comparison with OVA257–264-primed Apoe/
CD8þ T cells, incubation with OVA257–264-primed Cblb/Apoe/
CD8þ T cells significantly reduced the survival of OVA257–264-pulsed
BMDMs (Figure 5E and F). These data indicate that the enhanced
cytotoxicity of CD8þ T cells, in conjunction with their increased
abundance (Figure 4A–C), provoked macrophage killing and necrotic
core formation in the plaques of Cblb/Apoe/ mice.
CD8þ T cell are the main drivers of
atherogenesis in Cblb/Apoe/mice
To further evaluate the contribution of Cblb/Apoe/ CD8þ T
cells to atherosclerosis, Cblb/Apoe/ or Apoe/ bone marrow
was transplanted into lethally irradiated Apoe/ recipient mice.
Following 6 weeks of recovery, antibody-mediated depletion of
CD8þ T cells was initiated and continued for 6 weeks until the assess-
ment of atherosclerosis in the aortic arch and aortic root (Figure 6A).
Anti-CD8 treatment successfully depleted circulating CD8þ T cells
in both Cblb/Apoe/ and Apoe/ recipients (Figure 6B). CD8þ T
cells were also successfully depleted in the lymphoid organs and only
a minor increase in CD4þ T cells was observed in Cblb/Apoe/
chimeras (Supplementary material online, Figure S3).
Haematopoietic CBL-B deficiency did not affect plaque area in the
aortic arch, which contained only very initial plaques (Supplementary
material online, Figure S4), but markedly increased plaque
Figure 5 Casitas B-cell lymphoma-B deficiency increases the inflammatory and cytotoxic propensity of CD8þ T cells. IFNc (A, B) and granzyme B (C,
D) producing CD3þCD8þ cells among in vitro-restimulated splenocytes isolated from Apoe/ and Cblb/Apoe/ mice (n= 7 for IFNc; n= 4 for
Granzyme B). Representative dot plots are shown (dotted line: Apoe/; solid line Cbl-b/Apoe/). (E, F) In vitro macrophage killing assay; Apoe/
and Cblb/Apoe/ splenocytes were cultured in the presence of ovalbumin peptide257–264 for 6 days, subsequently CD8þ T cells were isolated and
co-cultured with ovalbumin peptide257–264-pulsed CFSEhigh labelled bone marrow-derived macrophages and unpulsed CFSElow labelled bone mar-
row-derived macrophages (n= 4). Representative histograms are shown. Data are presented as mean ± standard deviation.











































inflammation as reflected by an increased abundance of CD45þ cells
(Figure 6C and D) and MAC3þ macrophages (Figure 6E). A trend to-
wards increased CD3þ T cell content in the plaques of haematopoietic
CBL-B-deficient mice was observed (Supplementary material online,
Figure S4). Depletion of CD8þ T cells prevented the increase in
CD45þ and CD68þ cells in the plaques of haematopoietic CBL-B-defi-
cient mice (Figure 6C–E), demonstrating that Cblb/Apoe/ cytotoxic
T cells drive plaque inflammation in the early stages of atherosclerosis.
In the aortic root, where more advanced plaques were present,
haematopoietic deficiency of CBL-B resulted in a 1.8-fold increase in
lesion area (Figure 7A and B). Depletion of Cblb/Apoe/ CD8þ T
cells prevented this increase (Figure 7A and B) and ameliorated plaque
inflammation, as reflected by the decrease in CD45þ cells (Figure 7C).
Although MAC3þ content was not affected by haematopoietic CBL-
B deficiency (Figure 7D), depletion of CD8þ T cells prevented the in-
crease in necrotic core formation that was observed in
Cblb/Apoe/ bone marrow chimeras (Figure 7E and F). This ex-
periment, which demonstrates that depletion of CD8þ T cells
improves plaque inflammation and halts the progression of athero-
sclerosis in CBL-B-deficient bone marrow chimeras, indicates that
the atheroprotective effect of CBL-B predominantly relies on its
function in cytotoxic T cells.
Discussion
Here, we report that CBL-B, the ‘natural inhibitor’ of T cell activation,
has a critical function in atherosclerosis. The expression of CBL-B in
human atherosclerotic plaques is lower in advanced lesions when
compared with initial lesions and negatively correlated with necrotic
core area, indicating that CBL-B expression decreases during the pro-
gression of atherosclerosis. Absence of CBL-B aggravates initial ath-
erosclerosis in Apoe/ mice by inducing an atherogenic phenotype
in macrophages and accelerates the progression towards advanced
atherosclerotic lesions with large necrotic cores. This phenotype
results from an increase in CD8þ T cell numbers in CBL-B-deficient
mice, in conjunction with an enhanced inflammatory and cytotoxic
potential of Cblb/Apoe/ CD8þ T cells, which provoked macro-
phage death, as illustrated in our schematic model (Take home figure).
Circulating levels of activated CD8þ T cells are increased in
patients with coronary artery disease and CD8þ T cells are abun-
dantly present in human atherosclerotic lesions, where they outnum-
ber CD4þ T cells.3 Experimental studies have attributed a
detrimental role to CD8þ T cells in atherosclerosis as antibody-
mediated depletion of CD8þ T cells in Apoe/ mice mitigated ath-
erosclerosis by reducing the number of circulating proinflammatory
Figure 6 Depletion of Cblb/Apoe/ CD8þ T cells reduces inflammation in initial atherosclerotic plaques. (A) Apoe/ mice were lethally irradi-
ated and reconstituted with Apoe/ or Cblb/Apoe/ bone marrow and either treated with a CD8þ T cell depleting antibody or isotype control
for 6 weeks. (B) CD8þ T cell numbers in the blood of isotype and anti-CD8-treated mice. (C, D) Immunohistochemical quantification of the relative
number of CD45þ cells. And representative pictures of CD45-stained aortic arch sections containing initial atherosclerotic plaques. Scale bar:
100lm. (E) Quantification of plaque macrophage content. Data are presented as mean ± standard deviation (n= 11–14).








































.monocytes and hampering macrophage accumulation and apoptosis
in the plaque.6 Accordingly, adoptive transfer of CD8þ T-cells aggra-
vated atherosclerosis and increased necrotic core formation in
Apoe/Rag/ mice, due to granzyme B- and perforin-induced
macrophage death, resulting in clinically unfavourable high-risk pla-
ques.5 In the current study, we confirmed that an excess of CD8þ T
cells is detrimental in atherosclerosis, particularly due to the increase
in CD8þ T cell-mediated macrophage apoptosis and necrotic core
formation.
One cause of the increase in CD8þ T cells in Cblb/Apoe/ mice
is the lower susceptibility to Treg-mediated suppression. A similar
phenotype has been found in Cblb/ CD4þ T cells, which had devel-
oped resistance to TGFb due to SMAD7-mediated down-regulation
of TGFbR-II.16 In our study, CBL-B-deficient CD8þ T cells also
expressed less TGFbR-II, rendering them less prone to TGFb-medi-
ated Treg suppression. Furthermore, Tregs suppress T cell prolifer-
ation by capturing IL2, thereby limiting IL2-dependent T-cell
proliferation.17 We found that Cblb/Apoe/ CD8þ T cells secrete
more IL2 than Apoe/ CD8þ T cells, lowering their sensitivity to
Treg-mediated reductions in IL2. In addition, we demonstrate that
CBL-B promotes the suppressive effects of Tregs, which contrasts
previous findings that showed no effect of CBL-B ablation on Treg-
mediated suppression in in vitro polyclonal CD8þ T-cell proliferation
assays.18 This discrepancy might be due to the use of stimulating anti-
CD28 and anti-CD3 beads in our study vs. irradiated splenocytes and
CD3 stimulation in the earlier reports.18 In such an experimental
setup, Tregs can modulate antigen-presenting cells, interfering with T
cell activation, in addition to the suppressive effects on CD8þ T cells.
In addition to the significant effect on CD8þ T cells, CBL-B defi-
ciency also resulted in an atherogenic phenotype in monocytes and
macrophages, characterized by an increased migratory potential,
increased cytokine production and lipid uptake. Little is known about
the function of CBL-B in cells of myeloid origin, but it has been dem-
onstrated that CBL-B mediates TLR4 ubiquitination and impedes the
association of the adhesion proteins Lymphocyte Function-
associated Antigen 1 (LFA-1) and Intercellular Adhesion Molecule 1
(ICAM-1), thereby inhibiting adhesion and diapedesis.19 In other dis-
ease models, such as diet-induced obesity and sepsis, CBL-B defi-
ciency enhanced the infiltration of macrophages into adipose tissue,
causing insulin resistance in obesity, and excessive macrophage infil-
tration into the lung during sepsis.11,12 Our study shows that CBL-B
deficiency not only increased the migratory potential of monocytes
Figure 7 The progression of atherosclerosis is hampered in CD8þ T cell-depleted haematopoietic Cbl-b/Apoe/ chimeras. (A) Aortic roots of
20-week-old haematopoietic Apoe/ and Cblb/Apoe/ chimeras analysed for the amount of atherosclerosis. (B) Representative pictures of
haematoxylin and eosin-stained aortic root cross-sections containing advanced atherosclerotic plaques. Scale bar: 500lm. (C–E) Quantification of
plaque CD45þ cells, MAC3þ cells and necrotic core area in plaques of the aortic roots. Representative pictures are shown. The black line indicates
the necrotic core. Scale bar: 200lm. Data are presented as mean ± standard deviation (n= 14–18).



















































and macrophages, but also increased the production of inflammatory
mediators, which accelerates plaque initiation. Accordingly, we found
that depletion of CD8þ T cells in haematopoietic Cblb/Apoe/
mice did not affect lesion formation in the very early stage of athero-
sclerosis, which is primarily monocyte/macrophage-driven. In the
later stages of atherosclerosis, depletion of CD8þ T cells reduced
plaque area, plaque inflammation and necrotic core formation, indi-
cating that the progression of atherosclerosis in CBL-B-deficient
mice was predominantly driven by CD8þ T cells.
Conclusion
In summary, this study demonstrates that CBL-B puts a brake on
CD8þ T cell activation during atherogenesis, thereby inhibiting pla-
que inflammation and progression towards a clinically unfavourable
high-risk plaque phenotype. Although our experimental results
should be extrapolated to patients with caution and the effects of tar-
geting ubiquitination in specific immune cells must be scrutinized be-
fore being translated into a clinical application, our study attributes a
critical role to CBL-B in the regulation of cytotoxic T cell-driven
responses in atherosclerosis and provides the basis for novel CBL-B-
targeting therapeutic strategies.
Supplementary material
Supplementary material is available at European Heart Journal online.
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